Basu, Ellen Marlese

Publications

Sort by

Co-Author Network

selected publications

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 41
An unusual case of opsoclonus-myoclonus-ataxia syndrome associated neuroblastoma: High-risk disease requiring immunotherapy. Pediatric blood & cancer. 2020 Letter GET IT
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell. 2020 Academic Article GET IT
Times cited: 477
Reduced-dose craniospinal irradiation for central nervous system relapsed neuroblastoma. Pediatric blood & cancer. 2020 Academic Article GET IT
Times cited: 5
Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experience. Pediatric blood & cancer. 2020 Academic Article GET IT
Times cited: 4
Characterization of on-target adverse events caused by TRK inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 26
Local Anesthesia With General Anesthesia for Pediatric Bone Marrow Procedures. Pediatrics. 2019 Academic Article GET IT
Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial. International journal of radiation oncology, biology, physics. 2019 Academic Article GET IT
Times cited: 9
Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial. JAMA oncology. 2018 Academic Article GET IT
Times cited: 67
Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions. JCO precision oncology. 2018 Academic Article GET IT
Times cited: 13
Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study. Oncoimmunology. 2018 Academic Article GET IT
Times cited: 54
Treatment and outcome of adult-onset neuroblastoma. International journal of cancer. 2018 Academic Article GET IT
Times cited: 18
MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-G_D2 immunotherapy. Oncotarget. 2017 Academic Article GET IT
Times cited: 8
Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival. Oncoimmunology. 2017 Academic Article GET IT
Times cited: 23
Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study. Pediatric blood & cancer. 2017 Academic Article GET IT
Times cited: 39
A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma. International journal of cancer. 2016 Academic Article GET IT
Times cited: 38
Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy?. Pediatric blood & cancer. 2016 Letter GET IT
Times cited: 1
Image-defined risk factors for nephrectomy in patients undergoing neuroblastoma resection. Journal of pediatric surgery. 2016 Academic Article GET IT
Times cited: 14
Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget. 2016 Academic Article GET IT
Times cited: 48
Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms. Pediatric blood & cancer. 2016 Academic Article GET IT
Times cited: 14
Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass. Journal of pediatric surgery. 2015 Academic Article GET IT
Times cited: 6
Osteochondroma in long-term survivors of high-risk neuroblastoma. 2015 GET IT
Times cited: 12
When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Letter GET IT
Times cited: 7
Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era. Cancer. 2014 Academic Article GET IT
Times cited: 31
Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody. Cancer. 2013 Academic Article GET IT
Times cited: 19
5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma. Bone marrow transplantation. 2012 Academic Article GET IT
Times cited: 5
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. Cancer. 2012 Review GET IT
Times cited: 37
Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia. 2012 Letter GET IT
Times cited: 59

more ...

less ...

Background

education and training

M.D., Albert Einstein College of Medicine of Yeshiva University 2004
Ph.D., Albert Einstein College of Medicine of Yeshiva University 2004
M.S., Albert Einstein College of Medicine of Yeshiva University 1999
B.S., State University of New York at Buffalo 1995

Contact

full name

Ellen Marlese Basu

VIVO Weill Cornell Medical College

Ellen Marlese Basu Assistant Professor of Pediatrics

Publications

selected publications

Background

education and training

Contact

full name